Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active

Toks Akerele1, Grazyna Galatowicz, Catey Bunce

  • 1Institute of Ophthalmology, Moorfields Eye Hospital, City Road, London, UK.

Insights

Highly active antiretroviral therapy (HAART) improves CD4+ and CD8+ lymphocyte function in HIV/AIDS patients. Interferon-gamma production increases with HAART, especially with higher CD4 counts, while Interleukin-2 production normalizes early in CD8+ cells.

Area of Science:

  • Immunology
  • Virology
  • Cellular Biology

Background:

  • HIV/AIDS significantly impairs CD4+ and CD8+ T-lymphocyte function.
  • Understanding T-cell cytokine profiles is crucial for assessing antiretroviral therapy efficacy.

Purpose of the Study:

  • To assess the impact of highly active antiretroviral therapy (HAART) on CD4+ and CD8+ lymphocyte cytokine production in HIV/AIDS patients.
  • To investigate the relationship between cytokine expression and clinical parameters like viral load and CD4+ T-cell counts.

Main Methods:

  • Single-cell flow cytometry was used to measure Interferon-gamma (IFNγ) and Interleukin-2 (IL-2) production by CD4+ and CD8+ lymphocytes.
  • Sixty-eight HIV patients were categorized based on HAART status, viral load, and CD4+ T-cell counts.

Main Results:

  • IFNγ production by both CD4+ and CD8+ lymphocytes was elevated in HIV patients on HAART compared to controls, particularly when CD4+ counts exceeded 200 cells/mm³.
  • CD4+ IL-2 production remained low despite HAART, while CD8+ IL-2 production improved significantly with HAART and normalized when viral load was <50 copies/ml.
  • Early normalization of CD8+ IL-2 production was observed even with modest increases in CD4+ T-cell counts.

Conclusions:

  • HAART effectively improves CD4+ and CD8+ T-lymphocyte responsiveness in HIV/AIDS patients.
  • IFNγ elevation correlates with significant CD4+ T-cell recovery, whereas CD8+ IL-2 normalization occurs earlier in HAART treatment.